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Abstract. Psychic disorders in patients, who suffer from chronic somatic diseases for a long time, can 
be grouped into one category called psychosomatic pathology. Co-morbid – psychosomatic – 
disorders are considered to be predictors of unfavourable prognosis significantly aggravating patients’ 
condition, quality of life and professional activity. It is important to timely diagnose and perform 
pharmacological correction of affective pathology. Special attention should be paid to patients, whose 
profession is associated with the operational activity. 110 railroad workers admitted to the in-patient 
department of the Non-state Health Care Facility “RoadHospital the Station Voronezh-1of JSC 
“Russian Railways” with the diagnosis “Chronic pancreatitis, recurrent” were examined in the study. 
On admission all patients were questioned using specialized diagnostic scales and questionnaires 
aimed at revealing of anxio-depressive disorders. The authors have found out negative impact of 
anxio-depressive disorders on the course of chronic pancreatitis with the development of stable pain 
syndrome, gastro-intestinal disorders, resistance to the performed pharmacotherapy, and decrease of 
reaction rate to presented stimuli. Examination of the patients suffering from chronic pancreatitis 
demonstrated that patients with MADD had more severe course of the disease. This manifested in 
more intensive pain syndrome, apparent symptoms of nausea, bitter taste in the mouth and diarrhea; 
these symptoms exceeded number of similar complaints in patients with chronic pancreatitis without 
MADD in 1.6 – 2.1 times. Tranquilizer “Adaptol” and anxiolytic “Afobazol” in combination with 
basic therapeutical medications efficiently eliminate gastroenterological and anxiety symptoms. 
However, “Adaptol” decreases rate of visual-motor reactions, whereas “Afobazol”, on the contrary, 
increases reaction rate to presented stimuli.  
Key words: chronic pancreatitis, anxio-depressive disorders, co-morbid pathology, psychotropic 
therapy, Adaptol, Afobazol, railroad workers. 
 
Introduction. Psycho-somatic disorder is 
considered to be a psychogenically conditioned 
pathological state manifestating as an acute somatic 
pathology, violation of the internal body functions and 
physiological systems, such as the digestive, respiratory, 
circulatory, urinary system; this results in a specific 
complex of symptoms representing body reaction on the 
development of pathological disorders [11]. 
Combination of psychic and somatic violations 
is a characteristic feature of psycho-somatic 
disorders. Fundamental principle of this branch of 
medicine is an idea that any disease is not restricted 
by the clinical symptoms only (nausea, vomiting, 
abdominal pain, diarrhea etc.), but is manifested at 
several levels: emotional – a disease causes certain 
emotions and feelings; cognitive – comprehension of 
a disease; integrative – the way how an individual 
perceives, evaluates his condition and sees himself in 
the existing situation [2, 3]. 
The most common psychic diseases appear to be 
anxiety and depressive disorders; their total amount 
in general medical practice is approaching to 50% 
[3]. In practice it is very difficult to differentiate one 
condition from another (co-morbidity is 40 – 80%); 
in such cases they give evidence of mixed anxiety-
depressive disorders (MADD) [5, 6, 7]. 
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Affective disorders developing under 
gastrointestinal (GI) pathology are of special attention. 
According to various data, digestive system disorders 
having psychogenic origin are recorded in 30 – 70% of 
patients admitted to the in-patient gastroenterology 
departments [8, 9]. In spite of the large amount of 
research studies devoted to the investigation of 
psychosomatics in patients with GI disorders, there are 
comparatively few data indicating to MADD and 
chronic pancreatitis co-morbidity. Only a small number 
of works demonstrate interrelations of psychological 
manifestations and peculiarities of the course of 
pancreatic disease (severity, pain intensity, 
morphological changes) [110, 11, 12, 13]. 
Development and clinical manifestations of 
MADD and chronic pancreatitis are pathogenically 
interrelated. GABAergic and serotoninergic systems are 
considered to be main components of pathogenesis. 
Reduce of GABAergic activity provides appearance of 
gastroenterological panic attacks, which are manifested 
as discomfort in the epigastric region, nausea, rectal 
reflexes [14]. Serotonin appears to be an important 
element of gastrointestinal disorders associated with 
inflammation; this is connected with the violation of the 
innervations activity [15, 16]. When the amount of 
serotonin reduces, pain sensitivity increases, and even 
slight irritation causes apparent pain syndrome [17]. 
Influence of neurotransmitters on the extramural nerve 
endings of the gland tissue providing transmission of 
sensor information to the central nervous system is 
intensified under the inflammatory reaction. 
Intensification of their stimulation is associated with 
nauseous sensation and intestinal dysmotility [18].  
Anxiety and depression aggravate the course of 
somatic pathology, result in delayed onset of the 
remission and lead to repeated hospitalizations 
negatively influencing professional activity [19, 20]. 
This fact is especially important for individuals, who 
work in the conditions of constant psycho-emotional 
stress, and psycho-traumatic (stressful) events 
including railroad workers (train operators, assistants 
of train operators, traffic controller) [21, 22]. 
Pharmacological correction of combined 
pathology containing neurotic disorders is 
sufficiently complicated, especially in individuals 
working as operators [23]. Pharmaceutical effect on 
the professional abilities of train drivers is considered 
to be the issue of the day all over the world [24]. 
More than ten countries (Germany, France, Spain and 
others) have lists of drug products with indication of 
their danger level that is specified depending on their 
effect on the central nervous system when being 
taken by vehicle operators [25].    
“Classification of drug products depending on 
the level of their negative effects on the 
professionally significant functions of train operators 
and other operators’ professions” developed by 
Tsfasman A.Z. et al. [23] in 2011 is currently a must 
in the Russian Federation when administering drug 
therapy for railroad workers.  
Thus, timely diagnostics, effective and safe 
MADD and chronic pancreatitis pathogenetic therapy 
are very important for the treatment of railroad 
workers. 
Materials and methods. The research study 
was made on the basis of the Clinical Pharmacology 
Department of the Voronezh N.N. Burdenko Medical 
University and Gastroenterology Department of the 
Non-state Health Care Facility “Road Hospital the 
Station Voronezh-1of JSC “Russian Railways”. 
110 railroad workers admitted to the in-patient 
department with the diagnosis “Chronic pancreatitis, 
recurrent” (section K86.1 “Other chronic 
pancreatitis" of the International Classification of 
Diseases, 10
th
 edition) were examine in the study. 
Among them there were 78 males and 32 females, 
average age 44.5±2.8, including 42 assistants of the 
train operators (38.2%), 29 train operators (26.4%), 
20 train hosts (18.2%) and 19 train traffic controllers 
(17.2%); 24 healthy railroad workers, average age 
42.4±1.7, formed a separate study group. 
On admission all patients were questioned using 
specialized diagnostic scales and questionnaires 
aimed at revealing anxio-depressive disorders. These 
questionnaires included Hospital Anxiety and 
Depression Scale HADS (anxiety/ depression), Zung 
Anxiety Rating Scale ZARS (self-evaluation of 
depression), Spielberger-Khanin test (personal and 
reactive anxiety), a questionnaire “Health, Activity, 
Mood” (CAH in Russian). The diagnose “Mixed 
anxiety and depressive disorder” was made according 
to the International Classification of Diseases, 10
th
 
edition (section F41.2 “Mixed anxiety and depressive 
disorder”). 
Modified graduated Visual Analogue Scale 
(VAS) was used to evaluate intensity of pain 
syndrome and gastroenterological symptoms; 
intensity of pain syndrome and dyspeptic disorders 
(nausea, bitter taste in the mouth, diarrhea) were 
assessed according to a 5-point system. 
Activity of the inflammatory process of the 
pancreas was defined on the level of serum amylase, 
pancreatic amylase and lipase in the biochemical 
blood assay. Ultrasound examination of the pancreas 
was performed to specify its sizes, boundaries, 
structure and parenchymal echo-genicity. 
Assessment of psycho-physiological functional 
status was performed using psycho-diagnostic 
complex “Select-M” («Селект-М» in Russian). 
Participants were tested in an isolated, sound proof, 
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darkened room. Intensity and lability of nerve 
processes were investigated by defining a simple 
motor response (m/sec) to the red signal, complex 
motor responses to green light and to red light taking 
into account decision-making time. To differentiate 
psycho-motor or motor inhibition critical frequency 
of fusion flicker (CFFF) test was performed. The 
reaction to a moving object including an average 
passing time value, an average response time out 
value was used to estimate balance between 
excitation and inhibition processes in the cerebral 
cortex. Study results were interpreted according to 
“Methodological instructions on performing psycho-
physiological examinations in the railway locomotive 
facilities” (№ 310y, Ministry of Railways of the 
Russian Federation, December 1, 1999) [26]. 
Pharmaco-economic analysis was performed 
using software application “Calculation of the 
individual treatment cost” (certificate of registration 
№2011610459, January 11, 2012) [27]. 
Statistical data were processed using software 
application “SPSS 9.0”; the mean value (X) of 
standard deviation was estimated by calculating a 
mean error of the arithmetical mean value (m). Non-
parametric Wilcoxon signed-rank test was used to 
estimate confidence rating. Correlation dependence 
was determined according to Spearman method. 
Results. Comparative analysis of two groups of 
patients was performed at the first stage of study to 
assess MADD influence on the course of chronic 
pancreatitis and psycho-physiological functions: 
patients with chronic pancreatitis (n=45) and patients 
suffering from chronic pancreatitis and MADD (n=65). 
The control group consisted of healthy railway workers 
(n=24); the rate of visual-motor reactions was the only 
parameter determined in this group. 
The analysis of the results according to psycho-
diagnostic scales giving an opportunity to diagnoseanxio-
depressive disorders has demonstrated that anxiety and 
depression level in patients with chronic pancreatitis and 
MADD on HADS (anxiety/ depression) and Zung 
(depression) scales exceeds similar findings in the group 
of patients with chronic pancreatitis without affective 
disordersin 1.9 – 2.6 times (p 0.01), and normative 
values in 1.3 – 2 times (Table 1). 
Table 1.  
Findings of psycho-diagnostic examination (X±m). 
 
Findings Normative values 
Patients with chronic 
pancreatitis  (n=45) 
Patients with chronic 
pancreatitis and MADD (n=65) 
HADS Scale 
HADS, anxiety, points ≤7 5,4±1,2 13,9±1,7** 
HADS, depression, points ≤7 3,8±0,9 9,2±2,1** 
Zung Scale 
Depression, points <50 34,1±1,7 63,9±2,1** 
Spielberger – Khanin test 
Personal anxiety,points ≤30 41,5±1,2 58,3±2,9** 
Reactive anxiety, points ≤30 30,5±2,6 59,1±2,2** 
Health, Activity, Mood test 
Health, points ≥5 4,2±0,3 2,2±0,5** 
Activity, points ≥5 5,3±0,2 3,3±0,7** 
Mood, points ≥5 4,4±0,7 3,1±0,3* 
Note: * - p0.01 – confidence rating with the results of patients suffering from chronic pancreatitis.  
 
Study of psycho-emotional sphere according to 
Spielberger-Khanin test has revealed an increased 
level of reactive and personal anxiety in 29 patients 
(64.4%) with chronic pancreatitis and in all patients 
(100%) with combined chronic pancreatitis and 
MADD pathology, maximally expressed in patients 
with co-morbid pathology. Alongside with the high 
level of anxiety a significant decrease of findings on 
the “Health, Activity, Mood” test was recorded in 
patients suffering from affective disorders; this fact 
gives evidence of negative self-evaluation (Table 1). 
Concerning somatic disorders all the examined 
patients complained of pain syndrome and dyspeptic 
disorders (nausea, bitter taste in the mouth, diarrhea). 
However, intensity of gastroenterological symptoms 
was different in the comparable groups. In patients 
with chronic pancreatitis having no any signs of 
anxiety and depression pain according to VAS Scale 
was moderate averaging 2.8±0.1 points (“a symptom 
is slightly revealed”, “a symptom is moderately 
revealed”), whereas patients with chronic pancreatitis 
and MADD evaluated intensity of stomach-ache of 
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psychogenic nature as 4.5±0.6 points (“a symptom is 
severely revealed”, “a symptom is very severely 
revealed”). Findings “nausea, bitter taste in the 
mouth, altered defecation pattern” in patients with 
combined pathology exceeded similar findings in 
patients suffering only from chronic pancreatitis in 
1.6 – 2.1 times (Table 2). 
Table 2. 
Gastroenterological findings according to VAS Scale (X±m). 
 
Findings 
Patients with chronic pancreatitis       
(n=45) 
Patients with chronic 
pancreatitis+MADD (n=65) 
Pain syndrome, points 2,8±0,1 4,5±0,6* 
Nausea, points 2,3±0,2 4,9±0,8** 
Bitter taste in the mouth, points 2,1±0,5 3,6 ±0,3* 
Altered defecation pattern (diarrhea), points 1,6±0,1 3,5±0,2** 
Note: * - p0.05, ** - p0.01 – confidence rating with the results of patients suffering from chronic pancreatitis. 
 
According to the results of biochemical blood 
assay estimating enzymatic status changes of serum 
amylase level, pancreatic amylase level and blood 
lipase were registered in 22 patients (33.8%) with 
chronic pancreatitis and MADD. Thus, the value of 
serum amylase was 124.5±2.9 U/l, level of pancreatic 
amylase achieved upper limit of normal being less than 
54.4±3.2 U/l, blood lipase averaged 67.3±1.9 U/l. The 
results obtained exceeded normal values in 1.2 times.  
In contrast to patients with neurotic disorders, 
elevated enzyme level was revealed in 34 testees 
(75.5%) of the group of patients with chronic 
pancreatitis and without MADD; that was by 55.2% 
more often comparing to patients with MADD. Serum 
amylase level amounted 206.7±4.7 U/l, pancreatic 
amylase level amounted 93,2±3,3 U/l, blood lipase level 
amounted 94,7±2,8 U/l; this exceeded normal values in 
1.6 – 2 times and similar values in the group of patients 
with combined chronic pancreatitis and MADD in 1.4 – 
1.7 times (p<0,05; p<0,05; p<0,01). 
According to ultrasound (US) examination of 
the pancreas diffuse changes of the organ tissue were 
revealed in all patients: irregular indistinct 
boundaries, elevation of echogenicity, inhomogeneity 
of parenchyma. However, increased sizes of a gland 
were observed in 73.3% of patients with chronic 
pancreatitis and in 20% of patients with chronic 
pancreatitis and MADD only. 
The obtained clinico-laboratory and instrumental 
data in the group of patients with chronic pancreatitis 
gave explanation to presence of gastroenterological 
complaints and supported principal diagnosis; 
whereas in the group of patients with combined 
pathology clinical findings to a greater extent 
indicated at presence of psycho-somatic disorders.  
Evaluation of psycho-physiological functions in 
patients with chronic pancreatitis and without MADD 
demonstrated average values of visual-motor 
reactions rate; this fact indicated at the stability of 
processes of psycho-motor reactions and was 
comparable to the test performance rate in the group 
of healthy railroad workers (Table 3).  
 
Table 3. 
Findings of psycho-physiological functions prior to initiating therapy(Х±m). 
 
Findings 
Control group          
(n=24) 
Patients with chronic 
pancreatitis  (n=45) 
Patients with chronic 
pancreatitis and MADD (n=65) 
Simple motor response, m/sec 351,3±18,9 350,8±12,3 510,3±10,4* 
CFFF, Hz 37,8±4,3 34,5±5,9 35,6±4,7 
Complex motor response to red light, m/sec 419±16,8 508,2±10,6 626,9±8,8* 
Complex motor response to green light, m/sec  461±21,6 452,5±19,5 685,3±17,1** 
Decision-making timered 115,4±22,8 135,6±19,6 179,5±18,3* 
Decision making timegreen 95,7±19,9 131,9±21,5 156,3±14,3 
Reaction to a moving object including an 
average passing time value, m/sec 
46,9±4,5 48,9±5,7 47,2±8,3 
Reaction to a moving object including an 
average response time out value, m/sec 
48,3±4,4 58,9±5,2 116,3±11,4** 
Note: * - p0.05, ** - p0.01 – confidence rating with the results of patients suffering from chronic pancreatitis. 
 
In the group of patients with co-morbid 
pathology aggravation of test results with 
manifestations of inhibiting reaction was registered 
in78.4% of cases. Investigation of simple motor 
response demonstrated increased time of task 
performance by 45.5% (р<0.05) comparing to the 
result of test performance rate in the group of patients 
without anxiety and depression. The amount of CFFF
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 at that was 35.6±4.7 Hz, which is considered to be 
an average value and against the background of low 
simple motor response values is interpreted as the 
decrease of psycho-motor reaction. Test performance 
time in case of complex motor response to red and 
green light, as well as decision-making time to red 
light was respectively by 23.3%, 51.4% and 32.3% 
low than in patients with chronic pancreatitis 
(р<0,05, p<0,01; р<0,05). When performing the 
reaction to a moving object test in patients with 
chronic pancreatitis and MADD, the response time 
out reaction to a presented stimulus was prevalent. 
Average response time out values of the reaction to a 
moving object were 2 times higher in the group of 
patients without MADD (р<0,01) (Table 3). 
The following observation groups were formed out 
at the second stage of research study considering 
character of the conducted therapy: the control group 
(n=45) – patients with chronic pancreatitis (principal 
disease) without signs of anxiety and depression 
receiving standard (basic) pharmacotherapy (enzymatic 
preparations, proton pump inhibitors, spasmolytic 
drugs, non-narcotic analgetics, antidiarrheal 
preparations); the 1
st
  group (n=25) – patients with 
combined chronic pancreatitis and MADD receiving 
only basic therapy against their principal disease; the 2
nd
 
group (n=20) patients with combined chronic 
pancreatitis and MADD receiving tranquilizer of 
nonbenzodiazepine series – 
Tetramethyltetraazabicyclooctandione (“Adaptol”) in 
addition to basic preparations; the medication was given 
in a daily dose 1000 mg divided into 2 intakes (500 mg 
twice a day) independently on a meal; the 3
rd
 group of 
testees (n=20) was patients with chronic pancreatitis 
and MADD simultaneously taking basic preparations 
and selective anxiolytic Fabomotizole (“Afobazol”) in 
daily dose 30 mg divided into 3 intakes (10 mg three 
times a day) after meal. 
After being discharged from the hospital all 
testees continued taking enzymatic preparations 
and proton pump inhibitors out-patiently for 14 
days. Psychotropic therapy was being performed 
up to 30 days.  
The effectiveness and safety of treatment was 
evaluated on the 7
th
, 14
th
 and 30
th
 days of the 
treatment onset. Unfavourable side effects were 
being monitored during the whole period of 
observation for patients.  
Significant decrease of the anxiety component 
was registered according to the HADS Scale 
against the background of psychotropic drugs 
administration. Anxiety value in the 2
nd
 group of 
patients taking “Adaptol” decreased from 13.6±1,8 
to 10,8±0,7 points (р<0,05) on the 7th day of the 
therapy, to 8,9±0,4 points (р<0,05) on the 14th day 
of the therapy, to 7,8±0,8 points (р<0,01) on the 
30
th
 day of examination. In the 3
rd
 group of patients 
taking “Afobazol” anxiety level also reduced from 
13.9±2,1 to 10,2±0,6 points (р<0,05) on the 7th day 
of the therapy, to 9,3±1,2 points (р<0,01) in two 
weeks after administering the preparation, to 
7,9±0,8 points (р<0,01) on the 30th day of the 
therapy (Figure 1). 
In contrast to patients, who were given 
pharmacological correction of MADD, anxiety level in 
the 1
st
 group of patients receiving only basic 
preparations was not significantly altered: 14±2,2 points 
before treatment, 13,3±2,6  points on the 7th day of the 
therapy,  13,6±3,1 points on the 14th day,  13,8±1,4 
points on the 30
th
 day; this exceeded upper normal 
limits in 1.9 times (Figure 1). 
 
Figure 1. Dynamics of the anxiety level according to the HADS Scale against the background of the complex therapy.  
Note: * - p<0,05, ** - p<0,01- confidence rating with the results of examination before the treatment onset. 
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Control of the depression level according to 
the HADS and Zung Scales on the 7
th
 and 14
th
 day of 
the therapy did not reveal significant dynamics of the 
indicated value in both - patients receiving 
anxiolytics (“Adaptol”, “Afobazol”) and patients, 
who were administered only basic therapy of chronic 
pancreatitis. The depression value according to 
HADS and Zung Scales in the 1
st
 group of patients 
was at the same level on the 30
th
 day of examination, 
whereas it had a statistically non-significant tendency 
to reduce in the 2
nd
 and 3
rd
 groups. 
According to Spielberger-Khanin test the 
reactive anxiety value in the control group was 
28,6±2,2 points against the background of the basic 
therapy on the 14
th
 day of treatment; the obtained 
values were the same on the 30
th
 day of examination. 
Personal anxiety level had no changes during the 
whole course of the therapy being 37,5±2,1 points on 
the 7
th
 day of treatment, 42,6±2,8 points on the 14th 
day and 38,6±3,2 points on the 30th day. Results 
demonstrated low level of reactive anxiety and 
moderate level of personal anxiety (Table 4). 
Table 4. 
Dynamics of the anxiety values according to Spielberger-Khanin test against  
the background of pharmacotherapy (Х±m). 
 
Value Before treatment 7
th
 day of treatment 14
th
 day of treatment 30
th
 day of treatment 
Control group (n=45) 
Personal anxiety, points 41,5±1,2 37,5±2,1 42,6±2,8 38,6±3,2 
Reactive anxiety, points 30,5±2,6 32,6±3,5 28,6±2,2 28,3±2,9 
1
st
 group (n=25) 
Personal anxiety, points 61,3±2,1 58,7±1,8 53,5±1,9 65,8±3,6 
Reactive anxiety, points 56,7±0,9 52,3±0,5 53,6±1,2 54,2±2,8 
2
nd
 group (n=20) 
Personal anxiety, points 59,7±1,9 55,2±2,4 44,1±2,2* 45,6±1,9* 
Reactive anxiety, points 60,2±1,2 54,3±2,4 48,3±1,6* 42,6±1,6* 
3
rd
 group (n=20) 
Personal anxiety, points 63,2±2,2 58,2±1,7 48,7±2,4* 47,8±2,1* 
Reactive anxiety, points 56,5±1,2 49,7±2,7 37,4±4,2** 32,4±3,5** 
Note: * - p<0,05, ** - p<0,01- confidence rating with the results of examination before the treatment onset. 
 
In the 1
st
 group of patients with co-morbid 
pathology, who were given therapy only for chronic 
pancreatitis, values of personal and reactive anxiety 
during the whole period of in-patients and out-patients 
treatment were at the same level as before treatment 
being more than 46 points (high level of anxiety). 
A significant decrease of anxiety values was 
registered on the 14
th
 day of the therapy against the 
background of “Adaptol” and “Afobazol” 
administration. On the 30
th
 day of examination personal 
and reactive anxiety values in patients of the 2
nd
 group 
receiving “Adaptol” were at the obtained level being 
less than 46 points (moderate anxiety). In contrast to the 
2
nd
 group of patients intensity of reactive anxiety 
significantly reduced in patients of the 3
rd
 group taking 
“Afobazol” – by 42.6% comparing to the initial level 
and obtained 32,4±3,5 points (< 30 points is 
considered to be low level of anxiety).  
According to the results of “Health, Activity, 
Mood” test health and mood findings in patients of 
the control group tended to increase amounting to 
5,8±0,2 points (p<0,05) and 5,4±0,2 points 
respectively (p<0,05) on the 14
th
 day of treatment. 
Activity findings were at the sufficiently high level of 
5,5±0,2 points as before treatment. On the 30th day of 
examination health, activity, mood findings were 
within normal limits (more than 5 points) (Table 5). 
In the 1
st
 group of patients with chronic 
pancreatitis and MADD, who were given only 
standard pharmacotherapy, there were no significant 
improvements on the 7
th
, 14
th
 and 30
th
 days according 
to “Health, Activity, Mood” test. Health, activity and 
mood values in patients were at the same low level as 
before treatment being no more than 3.4 ±0.5 points.   
Positive self-evaluative dynamics of the patients’ 
condition according to “Health, Activity, Mood” test 
was recorded in the 2
nd
 and 3
rd
 group of patients with 
combined pathology taking tranquilizers alongside with 
basic preparations in 2 weeks of pharmacotherapy. 
Thus, health and mood values increased by 78.8% and 
30.5% respectively (p<0.01, p<0.05) on the 14
th
 day of 
treatment obtaining 5 and more points score on the 30
th
 
day of treatment. Activity level at that was low during 
the whole period of study. Opposed to “Adaptol”, 
“Afobazol” had a positive impact not only on the health 
and mood, but also on the activity level. All findings 
tended to increase by 73.9%, 37.5 % and 53.3% 
respectively (p<0,05, p<0,01) on the 14
th
 day of 
treatment obtaining more than 5 points score on the 30
th
 
day of examination. 
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Table 5. 
Results of psychological test according to “Health, Activity, Mood” questionnaire against the background  
of pharmacotherapy (Х±m). 
Value Before treatment 7
th
 day of the therapy 14
th
 day of the therapy 30
th
 day of the therapy 
Control group (n=45) 
Health, points 4,2±0,3 4,8±0,1 5,8±0,2* 5,6±0,2 
Activity, points 5,3±0,2 5,2±0,5 5,5±0,2 5,3±0,3 
Mood, points 4,4±0,7 4,6±0,2 5,4±0,4* 5,4±0,2* 
1
st
 group (n=25) 
Health, points 2,5±0,7 2,9±0,3 3,2±0,6 2,7±0,3 
Activity, points 3,5±0,3 3,1±0,5 3,4±0,5 2,9±0,2 
Mood, points 2,9±0,1 2,2±0,2 2,5±0,2 3,4±0,2 
2
nd
 group (n=20) 
Health, points 1,9±0,5 2,8±0,3 3,4±2,2** 5±0,3** 
Activity, points 3,1±0,3 3,3±0,2 2,9±0,4 3,7±0,5 
Mood, points 3,6±0,2 4,2±0,2 4,7±0,4* 5,2±0,3** 
3
rd
 group (n=20) 
Health, points 2,3±0,5 3,9±0,2 4±0,2** 5,4±0,6** 
Activity, points 3,2±0,2 3,5±0,5 4,4±0,3* 5,2±0,2** 
Mood, points 3±0,2 4,2±0,1 4,6±0,2* 5,2±0,2** 
Note: * - p<0,05, ** - p<0,01- confidence rating with the results of examination before the treatment onset. 
 
According to VAS reduction of pain syndrome 
from 2,8±0,1 points to 1,6±0,1 points (p<0,01) was 
registered in the group of patients with chronic 
pancreatitis and without MADD on the 7
th
 day of 
pharmacotherapy with the followed positive dynamics 
on the 14
th
 day of therapy when pain intensity in 86.8% 
of patients amounted to 1 point (p<0,01); that indicated 
at the “lack of symptom”. On further examination 
93.3% of patients reported the pain intensity being 
equal to1 point (p<0,01) when completing VAS 
questionnaire in 30 days after the treatment onset. On 
the contrary, no positive dynamics was observed on the 
value “stomach-ache of psycho-genic nature” in 
patients of the 1
st
 group with combined pathology on 
the 7
th
, 14
th
 and 30
th
 days of the therapy. In the 2
nd
 group 
of patients taking “Adaptol” pain intensity level 
decreased from 3,9±0,2 to 2,5±0,6 points (p<0,05) on 
the 14
th
 day and to 1,8±0,2 points (p<0,01) on the 30th 
day of the therapy. In the 3
rd
 group of patients receiving 
“Afobazol” a significant decrease of pain syndrome 
from 4,3±0,1 to 2,7±0,8 points (p<0,05) was registered 
as early as on the 7th day of the therapy with the 
followed tendency to reduce up to 1,5±0,1 points 
(p<0,01) on the 14
th
 day of examination; that was 
comparable with the results of treatment in patients of 
the control group with chronic pancreatitis. On the 30
th
 
day of examination the value “stomach-ache of psycho-
genic nature” remained at the obtained level - 1,5±0,2 
points (p<0,01) (Figure 2). 
Evaluation of dynamics of other 
gastroenterological symptoms in patients of the control 
group revealed gradual decrease of nausea intensity, 
bitter taste in the mouth and diarrhea. On the 7
th
 day of 
treatment nausea intensity decreased from 2,3±0,2 to 
1,9±0,6 points (р<0.05), bitter taste in the mouth – from 
2,1±0,5 points to 1,7±0,4 and diarrhea – from 1,6±0,1 
points to 1,3±0,3 points. On the 14th day of treatment of 
chronic pancreatitis exacerbation the above-mentioned 
values in 87.7% of patients did not exceed 1 point score 
(p<0,01; p<0,01; р<0,05), that indicated at the lack of 
gastroenterological manifestations. On the 30
th
 day of 
the therapy no patients complained of gastrointestinal 
disorders.  
Patients of the 1
st
 group reported about dyspeptic 
disorders at the same level as before the treatment 
onset comparing to patients of the control group. 
During the whole course of treatment severity of 
nausea, bitter taste in the mouth and diarrhea were 
equal to 3 – 4 points; this indicated at the 
“moderately revealed” and “severely revealed” 
symptoms. Diarrhea status decreased by 23.7% 
(p0.05) on the 30th day of the therapyonly. 
When performing complex treatment with 
application of psychotropic preparation severity of 
dyspeptic disorders also tended to decrease. In 
patients of the 2
nd
 group, who received “Adaptol” 
alongside with the basic therapy, somatic findings 
improved  on the 14
th
 day of treatment – nausea 
severity decreased from 4,7±0,2 to 2,5±0,9 points 
(p0.01), diarrhea severity decreased from 3,9±0,2 to
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2,4±0,5 points (p0.05); complaints on the bitter taste 
in the mouth remained unchanged, its intensity level 
amounted 3,2±0,9 points as before treatment. On the 
30
th
 day of treatment severity level of nausea and 
diarrhea amounted 1-2 points (p<0,01), this indicated 
at the “slightly revealed symptom”. Severity of 
nausea and diarrhea at that amounted 1 point (“lack 
of symptom”) in 45% of patients. Severity of the 
bitter taste in the mouth was without essential 
dynamics - 2,9±0,4  points. In contrast to “Adaptol” 
intake “Afobazol” administration allowed receiving 
therapeutical results as early as the 7
th
 day of 
treatment; this was manifested in significant decrease 
of complaints on nausea from   4,6±0,2 to 3,4±1,2 
points (p<0,05), bitter taste in the mouth - from 
4,05±0,7 to 3,2±0,3 points (p<0,05); severity of 
diarrhea tended to decrease from 3,8±0,2 to 3,2±0,3 
points. On the 14
th
 day of treatment the above-
mentioned symptoms did not exceed 2.6±0.2 points; 
on the 30
th
 day of examination 55% of patients did 
not complain of nausea, bitter taste in the mouth and 
diarrhea (Figure 2). 
 
 
 
 
 
Figure 2. Dynamics of gastroenterological symptoms against the background of the therapy.  
Note: * - p<0,05, ** - p<0,01- confidence rating with the results of examination before the treatment onset. 
 
Control of biochemical findings against the 
background of the performed treatment demonstrated 
favourable effect of basic and complex therapy on the 
enzymatic status; this was manifested by the 
significant decrease of serum amylase, pancreatic 
amylase and blood lipase level. 
Analysis of the rate of visual-motor reactions in 
the group of patients with chronic pancreatitis having 
no MADD (the control group), who received basic 
preparations, showed that there were no negative 
changes in the rate of visual-motor reactions; this 
indicated at the safety administration of preparations 
applied for the treatment of chronic pancreatitis in the 
context of professional operational activity.  
The rate of visual-motor reactions in patients 
with chronic pancreatitis and MADD, who received 
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only basic preparations (the 1
st
 group) was not altered 
during the whole course of in-patient and out-patient 
treatment. Rate of a simple motor response, a 
complex motor response, a reaction to a moving 
object was low with prevailing processes of 
inhibition and decrease of psycho-motor reaction. 
In the 2
nd
 group of patients, who were 
additionally administered “Adaptol”, test 
performance time of a simple motor response 
increased by 32% comparing to the initial level 
(p<0.05) on the 14
th
 day of treatment; decision-
making time (to green light) tended to increase by 
27% comparing to the given parameter on the 14
th
 
day of examination (p<0.05). The results obtained 
were interpreted as the tendency to slow the rate of 
visual-motor reactions (Table 6). 
Table 6. 
Findings of psycho-physiological functions in patients with chronic pancreatitis and MADD against the background  
of complex therapy including “Adaptol”(Х±m). 
Findings 
Before 
treatment 
7
th
 day of 
treatment 
14
th
 day of 
treatment 
30
th
 day of 
treatment 
Simple motor response, m/sec 465,2±8,7 478,3±12,9 615,7±11,5* 614,2±12,9* 
CFFF, Hz 33,6±2,5 38,9±4,7 36,6±7,2 34,3±2,9 
Complex motor response to green light, m/sec 698,1±11,4 697,5±15,8 679,3±13,9 665,4±16,7 
Complex motor response to green light, m/sec 701,5±17,3 679,5±12,1 686,4±10,4 698,7±11,8 
Decision-making timegreen 156,4±15,6 147,2±15,6 158,3±12,5 198,7±16,8
#
 
Decision-making timered 176,4±12,4 167,3±18,2 166,9±22,6 169,7±15,8 
Average passing time, m/sec 50,1±4,9 44,6±5,2 58,7±7,2 47,3±5,7 
Average response time out value, m/sec 110,2±9,6 114,3±8,3 117,3±4,6 112,6±6,6 
Note: * - p<0,05 - confidence rating with the results of examination before the treatment onset; 
# -p<0,05  p<0,05 -  confidence rating with the results of examination on the 14
th
 day of treatment. 
 
In contrast to “Adaptol” intake administration of  
“Afobazol” reduced task performance time: 
performance time of a simple motor response 
decreased by 22.8% on the 7
th
 day of therapy 
(p<0.05); performance time of a complex motor 
response to green light decreased by 30.2% (p<0.05), 
to red light – by 25.4% (p<0.05) on the 14th day of 
treatment; a reaction to a moving object including 
average response time out value decreased by 19.5%, 
a reaction to a moving object including average 
passing time value remained unchanged. In 2 weeks 
of anxiolytic “Afobazol” intake psycho-physiological 
findings reached average values of reaction to the 
presented stimulus typical for patients without 
MADD. On the 30
th
 day of treatment performance 
time of a simple motor response, CFFF, a complex 
motor response, a reaction to a moving object 
reached normative values conforming with the 
average reaction time to a signal (Table 7). 
Table 7. 
Findings of psycho-physiological functions in patients with chronic pancreatitis and MADD against the background  
of complex therapy including “Afobazol”(Х±m). 
Findings Before treatment 7
th
 day of 
treatment 
14
th
 day of 
treatment 
30
th
 day of 
treatment 
Simple motor response, m/sec 472,5±12,9 364,3±9,2* 325,8±8,9 337,7±10,3 
CFFF, Hz 38,8±2,9 40,6±4,8 39,7±6,9 37,4±7,5 
Complex motor response to green light, 
m/sec 
718,2±12,2 686,9±13,9 501,5±7,7* 513,7±8,9* 
Complex motor response to green light, 
m/sec 
689,2±10,2 702,3±8,4 513,9±7,2* 527,5±9,8* 
Decision-making timegreen 158,3±13,6 164,6±6,6 139,2±15,4 146,7±13,9 
Decision-making timered 184,7±15,8 179,5±14,7 149,2±15,4 156,7±13,9 
Average passing time, m/sec 44,2±8,3 45,6±7,3 51,7±3,9 43,8±5,9 
Average response time out value, m/sec 114,6±5,9 97,2±8,8 92,3±5,9* 94,3±7,8* 
Note: * - p<0,05, ** - p<0,01- confidence rating with the results of examination before the treatment onset. 
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At the third stage of study pharmaco-economic 
analysis was performed. For this all the patients were 
divided into 4 groups: the 1
st
 group (n=45) – patients 
with chronic pancreatitis, who received standard 
therapy for the principal disease; the 2
nd
 group (n=25) – 
patients with chronic pancreatitis and MADD, who 
were administered only basic preparation; the 3
rd
 group 
(n=20) – patients with chronic pancreatitis and MADD, 
who received anxiolytic “Adaptol” alongside with the 
standard treatment; the 4
th
 group (n=20) – patients with 
chronic pancreatitis and MADD, who were 
administered basic preparations and anxiolytic 
“Afobazol”.  
Performed pharmaco-economic analysis showed 
that treatment cost with gastroenterological 
preparations in the 2
nd
 group of patients with the 
combine pathology, who were not administered 
MADD correction, exceeded treatment cost of 
patients without affective pathology in 2 times 
(p<0.01) and in the group of patients receiving 
psychotropic medications “Adaptol” or “Afobazol” in 
1.6 and 1.5 times respectively (p<0.05) (cost of these 
medications was not taken into account) (Figure 3). 
 
 
Figure 3. Structure of direct medical costs at the in-patient stage. 
 Note: ## - p<0,01 – confidence rating of patients without MADD; * - p<0,05- confidence rating of patients receiving 
psychotropic preparations. 
 
Administration of psychotropic therapy to 
patients with MADD reduced spasmolytics intake by 
24.1%, analgesics intake by 23.9% and prokinetics 
intake by 28.5% in average, due to the effective 
elimination of the pain syndrome and dyspeptic 
disorders, since their intensity, as it was shown in the 
study, was related to the affective disorders. As a 
result, the therapy course with indicated preparations 
in patients with chronic pancreatitis and MADD 
receiving psycho-pharmacotherapy was practically 
approaching to the course dose of preparation intake 
in patients with chronic pancreatitis without signs of 
anxiety and depression, and therapeutical costs were 
consequently lower (Table 8). 
Table 8. 
Treatment of chronic pancreatitis with basic preparations. 
Group Spasmolytic, days Analgesics, days Prokinetics, days 
1
st
 group (n=45) 7,2±0,2 5,3±0,2 5,4±0,3 
2
nd
 group (n=25) 10,6±1,8 9,2±1,1 8,4±1,2 
3
rd
 group (n=20) 7,9±1,3 7,2±0,4 5,8±1,2 
4
th
 group (n=20) 8,2±1,4 6,8±1,5 6,2±1,4 
 
Complex therapy cost estimation considering 
cost of psychotropic preparations showed that 
“Adaptol” administration increased chronic 
pancreatitis and MADD treatment costs by 58.9%, 
whereas additional intake of “Afobazol” did not 
cause any significant price elevation, expenses at that 
rose by 26.6%. 
When evaluating an individual tolerability of 
administered psychotropic preparations, patients were 
interviewed to reveal adverse drug reaction (ADR) 
roubles 
##* 
 Lyubavskaya S.S., Chernov Y.N., Batishcheva G.A., Ushakov I.B., Goncharova N.Y. Complex therapy of 
chronic pancreatitis complicated by anxio-depressive disorders in railroad workers. Research result: 
pharmacology and clinical pharmacology. Vol. 2, №4 (2016): 73-86. 
83 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
typical for medications of tranquilizers group 
(sleepiness during the daytime, muscle relaxation and 
drug addiction), as well as side effects described in 
the instruction for medical use of “Adaptol” 
(dizziness, decrease of blood pressure, fatigue, 
dyspeptic disorders, allergic reactions) and 
“Afobazol” (allergic reactions, headache). 
No unfavourable effects or apparent health 
deterioration demanding cancellation of preparation 
or daily dose decrease were registered during the 
observation against the background of “Adaptol” and 
“Afobazol” therapy. 
When analyzing an individual tolerability of 
“Adaptol” 70% of patients complained of the 
apparent bitter taste in the mouth appearing right 
after the preparation intake and occurring during the 
whole therapy course. Besides, 55% of patients spoke 
about inconvenience of taking the preparation, which 
was related to the large size of a tablet. One patient 
noted intensification of dizziness during the first 10 
days of “Adaptol” therapy. However, no significant 
changes of blood pressure and pulse rate were 
registered at the checkups.  
10% of patients in the group of patients 
receiving “Afobazol” had sleeping disorders in the 
form of sleepiness during the daytime, which 
appeared on the 3-4 day of the treatment onset and 
compensated spontaneously on the 5-7 day of 
treatment. One patient, who was emotionally excited 
about his psycho-somatic status even before the 
psycho-pharmacorrection therapy onset, revealed 
prevalence of depressive component in the 
psychological testing, his reactive and personal 
anxiety was of high level; after the treatment course 
he reported about the development of “withdrawal 
symptoms” and, as a result,   drug addiction to 
“Afobazol”. 30% of patients did not agree with the 
frequent daily intake of the preparation (3 times a 
day), but they followed therapy regimen and fully 
completed it. 
Discussion. Examination of the patients 
suffering from chronic pancreatitis demonstrated that 
patients with MADD had more severe course of the 
disease. This manifested by intensive pain syndrome, 
apparent symptoms of nausea, bitter taste in the 
mouth and diarrhea exceeding similar complaints in 
patients with chronic pancreatitis having no any sign 
of anxiety and depression in 1.6-2.1 times. 
The fact that in75.5% of patients with chronic 
pancreatitis without MADD biochemical findings 
(serum amylase, pancreatic amylase, blood lipase)  
exceeded normative values in 2 times and US 
examination of the pancreas revealed its enlargement 
was of great significance. In contrast to patients without 
signs of anxiety and depression elevated level of 
enzymes was registered only in 38.8% of patients with 
combined pathology exceeding upper normative limits 
in 1.2 times, and US examination results indicated at the 
alteration of gland tissue without altering its sizes. The 
obtained data conform to research studies performed 
earlier, which demonstrated that it is impossible to 
reveal objective and significant gastro-intestinal 
changes in somatic patients with neurotic disorders 
during thorough repeated laboratory and instrumental 
investigations [28].  
Psychodiagnostic test results in patients with co-
morbid pathology revealed prevalence of the anxiety 
level that was 2 times higher than normative values 
according to HADS and Zung Scales. Survey results 
demonstrated that more than half a number of all 
patients were under conditions of constant stress for a 
long period of time (3 – 7 years). They reported about 
severe labour environment, shift basis working hours 
including night shifts, feeling of excessive responsibility 
at their working place. This supports the fact of 
developing anxio-depressive disorders mostly in 
patients, whose professional activity is subjected to 
long-lasting psycho-emotional overstrain [29, 30]. 
According to test results 100% of patients with co-
morbid pathology revealed elevated level of reactive 
and personal anxiety with the intensity of    58,3±2,9 
and 59,1±2,2 points (46 points and more indicate at the 
high level of anxiety).   The data obtained support the 
fact that elevation of situational and personal anxiety in 
locomotive crew workers increases risk of developing 
pathological somato-vegetative violations that cause 
inner organ disorders and deterioration of psycho-
physiological functions [31]. 
Assessment of combine pathology impact on the 
rate of visual-motor reactions appears to be an 
important aspect of study. The obtained results 
estimate presence of inhibiting reaction in 78.4% of 
patients. For example, rate of simple motor response 
was decreased in 45.5% comparing to the analogue 
reaction in patients without MADD (p0.05). CFFF 
at that was in the range of average values and in the 
context of low simple motor response values was 
interpreted as decrease of psycho-motor reaction 
(according to “Methodological instructions on 
performing psycho-physiological examinations in the 
railway locomotive facilities” № 310y, Ministry of 
Railways of the Russian Federation, December 1, 
1999). Test performance time for a complex motor 
response to green and red light was by 23.3% and 
51.4% more than in patients with chronic pancreatitis 
without affective pathology (p0.01, p0.05). 
According to results of the reaction to a moving 
object test average response time out values exceeded 
normative values amounting 116.7±11.4 m/sec 
(p0.01) with normative values of an average passing 
time – 47.2±8.3 m/sec. 
 Lyubavskaya S.S., Chernov Y.N., Batishcheva G.A., Ushakov I.B., Goncharova N.Y. Complex therapy of 
chronic pancreatitis complicated by anxio-depressive disorders in railroad workers. Research result: 
pharmacology and clinical pharmacology. Vol. 2, №4 (2016): 73-86. 
84 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
As a psychotropic therapy preparations patients 
were administered non-benzodiazepine tranquilizer 
Tetramethyltetraazabicyclooctandione (“Adaptol”) in a 
daily dose 1000 mg and selective non-benzodiazepine 
anxiolytic Fabomotizole (“Afobazol”) in a daily dose 30 
mg. Administration of the given preparations is 
pathogenically proved, since their action is aimed at the 
strengthening of GABAergic and  serotoninergic 
mechanisms in the brain [32, 33]. 
Impact of preparations on the rate of visual-motor 
reactions revealed during the research study appeared to 
be a restriction to apply “Adaptol” in train operators, 
assistants of train operators, traffic controllers at the out-
patient stage of treatment. Only train hosts continued 
receiving this preparation after being discharged from 
the hospital. In 2011 “Adaptol” was included in the list 
of the 1
st
 class preparations that are considered to be 
dangerous for the on-the-job administration for train 
operators and their assistants, since it can result in 
hypertension, fatigue and dizziness (study guidelines, 
IVth edition, updated and revised, “Medications and   
safety of train traffic” by Professor Tsfasman et al., 
2011). Changes indicating at the “Adaptol” potential to 
negatively influence the ability to drive transport 
vehicle and serve mechanisms causing possible 
decrease of blood pressure and fatigue were included in 
the Instruction for medical use of preparation (2011) 
[34].  
Observation results of patients suffering from 
chronic pancreatitis and MADD demonstrate that 
clinical use of preparations of the non-
benzodiazepine tranquilizer group “Adaptol” and 
“Afobazol” as a part of complex therapy allows 
conducting effective pharmacotherapy with 
favourable impact on gastrointestinal and anxiety 
symptoms. 
In the context of “Adaptol” administration the 
level of pain syndrome decreased by 35.8% on the 
14
th
 day of the in-patient treatment alongside with the 
reduction of nausea by 46.8% and diarrhea by 38.4%. 
The indicated findings amounted 1 point score in 
45% of patients on the 30
th
 day of the out-patient 
treatment; that indicated at the “lack of symptom”, 
though bitter taste in the mouth remained in more 
than half a number of patients during the whole 
course of therapy.  
“Afobazol”, in contrast to “Adaptol”, allowed 
obtaining therapeutical results as early as on the 7
th
 
day of treatment. Pain syndrome decreased by 37.2%, 
nausea – by 26% and bitter taste in the mouth – by 
20.9%. In a month after the onset of the preparation 
administration 55% of patients did not complain of 
dyspeptic disorders.  
In patients with chronic pancreatitis and MADD, 
who were not given psycho-pharmaco-correction, 
chronic pancreatitis treatment was ineffective. 
Patients were discharged with complaints on the 
apparent stomach-ache of psycho-genic nature, 
nausea and altered defecation pattern. Thus, MADD 
may provide developing of drug resistance and 
negative therapeutic outcome for patients with 
chronic pancreatitis,  
Dynamics evaluation of anxio-depressive 
disorders in the context of administration of psycho-
tropic drugs gave an opportunity to reveal a 
significant decrease of anxiety level on the 7
th
 day of 
“Adaptol” and “Afobazol” administration; their 
values  went down by 20.5% (p0.05) and 28% 
(p0.05) respectively. Depression level tended to 
decrease on the 30
th
 day of therapy. A significant 
decline of reactive and personal anxiety was 
registered on the 14
th
 day in the context of “Adaptol” 
and “Afobazol” administration, however, in 30 days 
of treatment “Afobazol” influence on situational 
anxiety was more evident and amounted 32.4±3.5 
points, whereas “Adaptol” decreased reactive anxiety 
level up to 42.6±1,6 points only. 
Research results aimed at the assessment of 
tranquilizers impact on the psycho-physiological 
functions in railroad workers demonstrated certain 
peculiarities. In the context of “Adaptol” 
administration  the time of a simple motor response 
test performance increased by 32% comparing to the 
initial level (p0.05), and decision-making time to 
green light tended to increase by 27% comparing to 
the same value on the 14
th
 day of treatment. The 
obtained alterations support the fact that preparation 
has a potential to reduce rate of visual-motor 
reactions that restricts use of the given medication in 
locomotive crew workers. 
“Afobazol”, on the contrary, reduced time of 
task performance. This manifested in the decrease of 
a simple motor response values by 22.8% (p0.05), a 
complex motor response to green light values by 
30.2% (p0.05), to red light by 25.4% (p0.05), a 
reaction to a moving object values by 19.5% 
(p0.05). The obtained results have an important 
significance for railroad workers, whose professional 
activity demanded boosting attention span and 
reaction fast rate. Positive “Afobazol” impact on the 
rate of visual-motor reactions has become a reason 
for execution of a patent for invention (“Way of 
increasing psycho-motor reaction rate using 
“Afobazol” anxiolytic”, patent № 2528110, 
registration date 16.07.2014) [35]; conducted psycho-
physiological research study gives an opportunity to 
determine an effective and safe preparation for
 Lyubavskaya S.S., Chernov Y.N., Batishcheva G.A., Ushakov I.B., Goncharova N.Y. Complex therapy of 
chronic pancreatitis complicated by anxio-depressive disorders in railroad workers. Research result: 
pharmacology and clinical pharmacology. Vol. 2, №4 (2016): 73-86. 
85 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
railroad workers when performing pharmacological 
correction of anxio-depressive disorders.  
Based on pharmaco-economic analysis and 
considering high efficiency and low cost of the 
course treatment a therapy design including 
anxiolytic “Afobazol” is considered to have higher 
priority. 
To conclude, it is necessary to report that results 
of the current study have practical significance for 
patients with combine pathology including chronic 
pancreatitis and anxio-depressive disorders, since 
conducted complex assessment of the gastrointestinal 
status, peculiarities of psycho-emotional sphere and 
psycho-physiological functions give an opportunity 
to determine pathogenic peculiarities of co-morbid 
diseases and choose the most rational scheme of 
pharmaco-correction. 
Conclusions. 
1. Combination of chronic pancreatitis and 
anxio-depressive disorders provide worsening of pain 
syndrome and gastro-intestinal disorders resulting in 
resistance to the conducted therapy. 
2. Anxio-depressive syndrome, co-morbid 
with chronic pancreatitis, reduces rate of visual-
motor reactions increasing performance time of a 
simple motor reaction by 45%, a complex motor 
reaction by 37% and a reaction to a moving object in 
2 times comparing to similar findings of patients with 
chronic pancreatitis without anxiety disorders. 
3. Complex therapy including administration 
of a tranquilizer “Adaptol” provides regress of 
anxiety on the 7
th
 day of treatment, 
gastroenterological symptoms on the 14
th
 day of 
treatment, whereas an “Afobazol” anxiolytic 
simultaneously eliminates both - anxiety and 
gastroenterology disorders, on the 7
th
 day of 
treatment. 
4.  “Afobazol” anxiolytic administration as a 
part of complex therapy in case of exacerbation of 
chronic pancreatitis ensures elevated rate of visual-
motor reactions in 80% of patients, whereas 
“Adaptol” tranquilizer affects psycho-physiological 
findings in 65% of cases. 
5. Additional administration of  an “Adaptol” 
tranquilizer increases treatment cost in 2.4 times, 
whereas application of “Afobazol” increases 
treatment cost in 1.4 times. 
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